A Prediction Model for Conversion from Normal Cognition to Mild Cognitive Impairment

The advent of biomarkers has allowed for the determination of Alzheimer disease (AD) pathology in the presymptomatic stage. Researchers from the BIOCARD study investigated whether AD biomarker measurements can predict conversion from normal cognition to mild cognitive impairment (MCI) in an individual. For 224 participants with normal cognition (mean baseline age, 57 years) the investigators recorded baseline age and education, neuropsychological assessments (Digit Symbol Substitution Test from the Wechsler Adult Intelligence Scale — Revised and the Verbal Paired Associates — Immediate recall from the Wechsler Memory Scale — Revised), cerebrospinal fluid (CSF) amyloid-β and phosphorylated tau levels, MRI brain right hippocampal volume and r…